Exhibit 10.2
EYEPOINT PHARMACEUTICALS, INC.
AMENDMENT NO. 2 TO THE 2019 EMPLOYEE STOCK PURCHASE PLAN
WHEREAS, EyePoint Pharmaceuticals, Inc. (the “Company”) maintains the EyePoint Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan, which was originally effective as of July 1, 2019 and amended as of June 22, 2021 (as amended, the “ESPP”);
WHEREAS, pursuant to Section 13(b) of the ESPP, the Compensation Committee (“Compensation Committee”) of the Board of Directors of the Company (the “Board”) may amend the ESPP at any time; provided that, the effectiveness of any amendment to the ESPP shall be contingent on approval of such amendment by the Company’s stockholders to the extent provided by the Board or applicable law (“Stockholder Approval”);
WHEREAS, the Compensation Committee, in consultation with legal and financial advisors, has determined that it is advisable and in the best interests of the Company and its stockholders to increase the number of shares of the Company’s common stock, $0.001 par value per share, reserved for issuance under the ESPP by 250,000 shares (the “ESPP Share Increase”);
WHEREAS, pursuant to Section 13(b) of the ESPP, in order to effect the ESPP Share Increase, Stockholder Approval must be obtained;
WHEREAS, the Compensation Committee has approved the ESPP Share Increase and has recommended that the Board adopt and approve the ESPP Share Increase subject to Stockholder Approval;
WHEREAS, the Board desires to amend the ESPP to provide for the ESPP Share Increase as set forth in this amendment to the ESPP (this “ESPP Amendment”), effective upon receipt of the Stockholder Approval; and
WHEREAS, capitalized terms used in this ESPP Amendment but not defined herein shall have the meaning given to them in the ESPP.
NOW, THEREFORE, the Board hereby amends the ESPP, effective upon receipt of the Stockholder Approval, as follows:
1. Section 3(a) of the ESPP is deleted and replaced in its entirety with the following:
3. SHARES SUBJECT TO THE PLAN
“(a) Share Reserve. Subject to adjustment as provided in Section 12, the maximum number of shares of Stock that may be issued pursuant to Options granted under the Plan (including any Non-423(b) Offering established hereunder) is Six-Hundred and Ten Thousand (610,000) shares. The shares of Stock reserved for issuance under the Plan may be authorized but unissued shares, treasury shares, or shares purchased on the open market.”
2. Except as specifically provided in and modified by this ESPP Amendment, the ESPP is in all other respects hereby ratified and confirmed and references to the ESPP shall be deemed to refer to the ESPP as modified by this ESPP Amendment, effective upon receipt of the Stockholder Approval.
A-12
Conformed copy to reflect amendments adopted through June 22, 2021.
EYEPOINT PHARMACEUTICALS, INC.
2019 EMPLOYEE STOCKPURCHASE PLAN, AS AMENDED
A-13
A-14
A-15
A-16
A-17
A-18
A-19
Illustrative Hypothetical Example of the Purchase Price calculation
Offering Period: August 1, 2019 - January 31, 2020
High sales price of EYPT Stock on August1, 2019: $2.30 Low sales price of EYPT Stock on August 1, 2019: $2.20
Average high and low sales price of EYPT Stock on August 1, 2019: $2.25
85% of average high and low sales price of EYPT Stock on August 1, 2019: $1.9125
High sales price of EYPT Stock on January 31, 2020: $3.50 Low sales price of EYPT Stock on January 31, 2020: $3.30
Average high and low sales price of EYPT Stock on January 31, 2020:$3.40
85% of average high and low sales price of EYPT Stock on January 31, 2020: $2.89
The lesser of the two 85% of average high and low sales price figures is $1.9125. Thus, the Purchase Price applicable for this hypothetical Offering Period is $1.9125 per Share of EYPT Stock.
A-20
A-21
A-22
A-23
A-24
***
A-25